North Sound Capital LLC v. Merck & Co Inc

938 F.3d 482
CourtCourt of Appeals for the Third Circuit
DecidedSeptember 12, 2019
Docket18-2317
StatusPublished
Cited by28 cases

This text of 938 F.3d 482 (North Sound Capital LLC v. Merck & Co Inc) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
North Sound Capital LLC v. Merck & Co Inc, 938 F.3d 482 (3d Cir. 2019).

Opinion

PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT _______________

Nos. 18-2317 _______________

NORTH SOUND CAPITAL LLC; NORTH SOUND LEGACY INTERNATIONAL; NORTH SOUND LEGACY INSTITUTIONAL; UNITED FOOD COMMERCIAL WORKERS LOCAL 500 PENSION FUND; COLONIAL FIRST STATE INVESTMENTS LTD.; CFSIL-CFS WHOLESALE INDEXED GLOBAL SHARE FUND; CFSIL-COMMONWEALTH GLOBAL SHARES FUND 4; CFSIL-COMMONWEALTH SPECIALIST FUND 13; CFSIL WHOLESALE GEARED GLOBAL SHARED FUND; CFSIL ATF CMLA INTERNATIONAL SHARE FUND; CFSIL-COMMONWEALTH GLOBAL SHARES FUND 6; CFSIL COMMONWEALTH SHARES FUND 2; CFSIL-CFS WHOLESALE ACADIAN GLOBAL EQUITY FUND; CFSIL-CFS WHOLESALE GLOBAL HEALTH & BIOTECHNOLOGY FUND; CFSIL-CFS WHOLESALE GLOBAL SHARE FUND,

Appellants

v.

MERCK & CO., INC. formerly known as SCHERING- PLOUGH CORPORATION; MERCK SCHERING- PLOUGH PHARMACEUTICALS; MSP DISTRIBUTION SERVICES (C) LLC.; MSP SINGAPORE COMPANY LLC; FRED HASSAN; CARRIE S. COX

On Appeal from the United States District Court for the District of New Jersey (D.N.J. No. 3-13-cv-07240) Honorable Freda L. Wolfson, U.S. District Judge

_______________

No. 18-2318

GIC PRIVATE LIMITED,

Appellant

MERCK & CO., INC. formerly known as SCHERING- PLOUGH CORPORATION; MERCK/SCHERING PLOUGH PHARMACEUTICALS; MSP DISTRIBUTION SERVICES (C) LLC; MSP SINGAPORE COMPANY LLC; FRED HASSAN; CARRIE S. COX

On Appeal from the United States District Court for the District of New Jersey (D.N.J. No. 3-13-cv-07241) Honorable Freda L. Wolfson, U.S. District Judge

No. 18-2319

2 GIC PRIVATE LIMITED,

MERCK & CO., INC.; MERCK/SCHERING-PLOUGH PHARMACEUTICALS; MSP DISTRIBUTION SERVICES (C) LLC; MSP SINGAPORE COMPANY LLC; RICHARD T. CLARK; DEEPAK KHANNA

On Appeal from the United States District Court for the District of New Jersey (D.N.J. No. 3-14-cv-00241) Honorable Freda L. Wolfson, U.S. District Judge

No. 18-2320

NORTH SOUND CAPITAL LLC; NORTH SOUND LEGACY INTERNATIONAL; NORTH SOUND LEGACY INSTITUTIONAL; UNITED FOOD COMMERCIAL WORKERS LOCAL 1500 PENSION FUND,

MERCK & CO., INC.; MERCK/SCHERING-PLOUGH

3 PHARMACEUTICALS; MSP DISTRIBUTION SERVICES (C) LLC; MSP SINGAPORE COMPANY LLC; RICHARD T. CLARK; DEEPAK KHANNA

On Appeal from the United States District Court for the District of New Jersey (D.N.J. No. 3-14-cv-00242) Honorable Freda L. Wolfson, U.S. District Judge

Argued: March 20, 2019

Before: SHWARTZ, KRAUSE, and BIBAS, Circuit Judges

(Opinion Filed: September 12, 2019)

Daniel Hume [ARGUED] Karina Kosharskyy Ira M. Press Meghan J. Summers Kirby McInerney 250 Park Avenue Suite 820 New York, NY 10177

Counsel for Appellants

Daniel J. Juceam Daniel J. Kramer [ARGUED] Theodore V. Wells, Jr.

4 Paul Weiss Rifkind Wharton & Garrison 1285 Avenue of the Americas New York, NY 10019

Counsel for Appellees

OPINION OF THE COURT _______________

KRAUSE, Circuit Judge.

In these consolidated appeals, we consider whether the Securities Litigation Uniform Standards Act (SLUSA) prohibits investors from bringing individual actions under state law if they exercise their constitutionally protected right to opt out of a class action. Hewing to SLUSA’s text, we conclude that these opt-out suits and the class actions from which these plaintiffs excluded themselves were not “joined, consolidated, or otherwise proceed[ing] as a single action for any purpose.” 15 U.S.C. § 78bb(f)(5)(B)(ii)(II). Accordingly, we will reverse the District Court’s dismissal of these suits and remand for further proceedings.

I. Background

This long-running dispute concerns allegations that two pharmaceutical manufacturers, Merck and Schering- Plough, stalled the release of damaging clinical trial results for their blockbuster drugs Vytorin and Zetia for years, tried to change the endpoint of the study to produce more favorable

5 results, and then concealed their role in pushing for the change.1 During this time, Merck and Schering-Plough allegedly made numerous statements touting the efficacy and commercial viability of Vytorin and Zetia. Plaintiffs allege that the delay allowed Schering-Plough to raise $4.08 billion through a public offering in August 2007, which the company then used to purchase another pharmaceutical company that would lessen its reliance on Vytorin and Zetia.

Amid several critical press reports and an incipient congressional investigation, Merck and Schering-Plough finally released the clinical trial results in January and March 2008. The data showed that “[i]n no subgroup, in no segment, was there any added benefit” from taking Vytorin, raising the possibility that the active-ingredient ezetimibe amounted to an “expensive placebo.” App. 165–66. Based on the results, the New England Journal of Medicine, along with several leading cardiologists, recommended that doctors prescribe Vytorin and Zetia only if other classes of drugs failed to control a patient’s cholesterol.

The devastating results for these popular anti- cholesterol drugs allegedly caused Merck’s and Schering- Plough’s stock price to plummet. Between December 11, 2007 and March 31, 2008, Schering-Plough’s common-stock price declined 52%, eliminating $23.63 billion in market

1 Vytorin and Zetia are anti-cholesterol drugs that operate differently than the leading treatment for high cholesterol, a class of drugs called statins. Statins reduce the synthesis of low-density lipoprotein in the liver, while Zetia inhibits the absorption of cholesterol in the small intestines. Vytorin combines Zetia with a statin manufactured by Merck called Zocor.

6 capitalization. And Merck’s stock price dropped 38%, amounting to around a $48 billion loss in market capitalization.

A. Investors File Putative Class Actions Against Merck and Schering-Plough

Faced with enormous losses, investors soon filed separate putative class actions in the District of New Jersey against Merck and Schering-Plough, alleging each made numerous material misrepresentations about Vytorin and Zetia. Over a year later, in September 2009, the District Court denied defendants’ motions to dismiss under the Private Securities Litigation Reform Act’s (PSLRA) heightened pleading standard. Three years after that, the District Court denied defendants’ motion for summary judgment and granted class certification.

The District Court then directed—as Rule 23(c)(2) requires—that investors receive notice of their right to opt out of the class actions. The court-approved notices provided investors with 45 days (that is, until March 1, 2013) to exclude themselves from the class actions. If they did so, the notices assured them, “you will not be bound by any judgment in this Action” and “will retain any right you have to individually pursue any legal rights that you have against any Defendants.” In re Merck & Co., Inc. Vytorin/ZETIA Sec. Litig., No. 2:08-cv-02177, ECF No. 266–1 at 11 (Dec. 19, 2012); In re Schering-Plough Corp. / ENHANCE Sec. Litig., No. 2:08-cv-00397, ECF No. 331–1 at 11 (Dec. 19, 2012).

After the opt-out period ended, the District Court approved the settlement agreements the class-action plaintiffs

7 reached with Merck and Schering-Plough. At the parties’ request, the District Court declined to provide class members with a second opportunity to opt out, but did offer opt-out investors 45 days to join the class actions and share in the recovery. In preliminarily approving the settlement agreements, the District Court reiterated that opt-outs “shall not be bound by the terms of the Settlement, the Stipulation, or any other orders or judgments in the Action.” In re Schering-Plough Corp. / ENHANCE Sec.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
938 F.3d 482, Counsel Stack Legal Research, https://law.counselstack.com/opinion/north-sound-capital-llc-v-merck-co-inc-ca3-2019.